잠시만 기다려 주세요. 로딩중입니다.

Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer

Annals of Surgical Treatment and Research 2020년 98권 6호 p.291 ~ 298
배수연 ( Bae Soo-Youn ) - Korea University College of Medicine Korea University Anam Hospital Department of Surgery

이정현 ( Lee Jeong-Hyeon ) - Korea University College of Medicine Korea University Anam Hospital Department of Pathology
배정원 ( Bae Jeoung-Won ) - Korea University College of Medicine Korea University Anam Hospital Department of Surgery
정승필 ( Jung Seung-Pil ) - Korea University College of Medicine Korea University Anam Hospital Department of Surgery

Abstract


Purpose: Our previous studies suggested that p53-positive triple-negative breast cancer (TNBC) should be more sensitive to chemotherapy than p53-negative TNBC. The aim of this study was to determine whether p53 expression in TNBC could predict response to neoadjuvant chemotherapy and the resulting prognosis.

Methods: From January 2009 to December 2017, TNBC patients who underwent neoadjuvant chemotherapy were reviewed, including a total of 31 TNBC patients who had clinical lymph node metastasis. The status of p53 expression in patients before and after chemotherapy was evaluated.

Results: Two patients (22.2%, 2 of 9) achieved pCR in p53(+) TNBC and 4 patients (50%, 5 of 10) achieved pCR in p53(?) TNBC. There was no correlation between pCR rate and p53 expression (P = 0.350). Based on prechemotherapy p53 expression, there was no significant difference in disease-free survival (DFS) between p53(+) TNBC and p53(?) TNBC (P = 0.335). However, after chemotherapy, p53(+) TNBC had shown higher DFS than p53(?) TBNC (P = 0.099). Based on prechemotherapy p53 expression, p53(+) TNBC had better overall survival (OS) than p53(?) TNBC, but the difference was not statistically significant (P = 0.082). After chemotherapy, p53(+) TNBC showed significantly better OS than p53(?) TNBC (P = 0.018).

Conclusion: Immunohistochemically detected p53 expression in TNBC could not predict the response to neoadjuvant chemotherapy. However, p53(+) TNBC had a better OS than p53(?) TNBC in patients who underwent neoadjuvant chemotherapy.

키워드

Immunohistochemistry; Neoadjuvant therapy; Prognosis; Triple negative breast neoplasms; Tumor suppressor potein p53
원문 및 링크아웃 정보
  
등재저널 정보